A COMMONLY-PRESCRIBED asthma drug could hold the key to slowing or even REVERSING the deterioration of cells in the brain, marking a significant step forward in the fight to beat dementia. Pioneering research by an Austrian team of scientists found montelukast, which is sold under the brand name Singulair and is used to treat asthma and allergic reacts including hay fever, actually reversed the ageing process in a study on rat brains.
The results are significant enough to warrant a clinical trial on people suffering from Parkinson’s disease. Dr Aigner said “structurally, the brain had rejuvenated…I think the drug reverses the damage associated with ageing.” Dr Aigner said: “We’ve restored learning and memory 100 per cent, to a level comparable with youth.”
Dementia charities have hailed the research as a possible breakthrough in the treatment of the illness, which affects one in six people over the age…
View original post 110 more words